TY - JOUR
T1 - NK3 receptor antagonists for the treatment of schizophrenia
AU - Meltzer, Herbert
AU - Prus, Adam
N1 - Funding Information:
Supported, in part, by grants from the William K Warren Foundation, Ritter Foundation and Stanley Medical Research Institute.
PY - 2006/6
Y1 - 2006/6
N2 - The ability of NK3 receptor antagonists to enhance dopaminergic, serotonergic, noradrenergic, cholinergic and GABAergic release in the limbic system, cortex, hippocampus and striatum, all of which have been implicated in schizophrenia and the mechanism of action of antipsychotic drugs, is a principal reason for interest in this class of drugs as a possible monotherapy or augmentation treatment for schizophrenia. In addition, two NK3 receptor antagonists, osanetant and talnetant, have been studied in patients with schizophrenia, with some evidence for efficacy (osanetant).
AB - The ability of NK3 receptor antagonists to enhance dopaminergic, serotonergic, noradrenergic, cholinergic and GABAergic release in the limbic system, cortex, hippocampus and striatum, all of which have been implicated in schizophrenia and the mechanism of action of antipsychotic drugs, is a principal reason for interest in this class of drugs as a possible monotherapy or augmentation treatment for schizophrenia. In addition, two NK3 receptor antagonists, osanetant and talnetant, have been studied in patients with schizophrenia, with some evidence for efficacy (osanetant).
UR - http://www.scopus.com/inward/record.url?scp=33846177867&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846177867&partnerID=8YFLogxK
U2 - 10.1016/j.ddstr.2006.11.013
DO - 10.1016/j.ddstr.2006.11.013
M3 - Review article
AN - SCOPUS:33846177867
SN - 1740-6773
VL - 3
SP - 555
EP - 560
JO - Drug Discovery Today: Therapeutic Strategies
JF - Drug Discovery Today: Therapeutic Strategies
IS - 4
ER -